A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

By Chu Quincy   Forouzesh Bahram   Syed Samira   Mita Monica   Schwartz Garry   Copper Joshua   Curtright Janet   Rowinsky Eric  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 359-367

Springer Publishing Company

Access to resources Recommend Favorite

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

By Paz-Ares Luis  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 729-740

Springer Publishing Company

Access to resources Recommend Favorite

Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases

By Scatena R.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 9, 2000-09 ,pp. : 2159-2165

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

By Pacey Simon  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 481-488

Springer Publishing Company

Access to resources Recommend Favorite

Levels of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 mRNAs in Patients with Primary Hypertension or Hypertension-induced Atherosclerosis

By Su W   Gao F   Lu J   Wu W   Zhou G   Lu S  

The Journal of International Medical Research, Vol. 40, Iss. 3, 2012-05 ,pp. : 986-994

Field House Publishing

Access to resources Recommend Favorite